Feasibility of a hospital outpatient day procedure for medication abortion at 13-18 weeks gestation: Findings from Nepal
Abortifacient Agents, Nonsteroidal
/ administration & dosage
Abortifacient Agents, Steroidal
/ administration & dosage
Abortion, Induced
/ adverse effects
Adolescent
Adult
Ambulatory Care
Feasibility Studies
Female
Gestational Age
Humans
Middle Aged
Mifepristone
/ administration & dosage
Misoprostol
/ administration & dosage
Nepal
Pregnancy
Pregnancy Trimester, First
Pregnancy Trimester, Second
Prospective Studies
Young Adult
Medical abortion
Medication abortion
Mifepristone
Misoprostol
Second trimester
Task-sharing
Journal
Contraception
ISSN: 1879-0518
Titre abrégé: Contraception
Pays: United States
ID NLM: 0234361
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
07
06
2019
revised:
21
08
2019
accepted:
26
08
2019
pubmed:
7
9
2019
medline:
22
9
2020
entrez:
7
9
2019
Statut:
ppublish
Résumé
To evaluate the safety, acceptability and feasibility of a one-day outpatient medication abortion service at gestations 13-18 weeks. Open-label prospective study in which participants received mifepristone 200 mg orally to swallow at home or at the clinic followed 24 h later by misoprostol 400 mcg buccally. They presented to the outpatient clinic 24-48 h after mifepristone for misoprostol 400 mcg buccally every three hours (no maximum dose). The primary outcome was successful abortion without transfer to overnight inpatient care. Secondary outcomes included time to abortion from initial misoprostol dose, safety, additional interventions and side effects. We enrolled 230 women from December 2017 to November 2018. Approximately nine of ten (n = 206, 89.6%) achieved a successful abortion without transfer to overnight care. Twenty-four were transferred to overnight inpatient care; of these 18 were to manage a complication, five for incomplete abortion and two by choice. Among these 24, three women experienced an SAE. The median time to successful abortion from time of the first misoprostol dose was 7.2 h (range: 0.75-92.3), with an average of three misoprostol doses. Most participants expelled the fetus and the placenta at or around the same time; median time between fetal and placental expulsion was 15 minutes (range: 0-4.5 h). Fifteen participants (6.6%) received more than five misoprostol doses and were transferred to inpatient care. Administration of more than five doses of misoprostol was associated with nulliparity. Provision of antibiotics (27.9%, n = 64), manual removal of placenta (15.3%, n = 35), uterotonics (4.4%, n = 10) and surgical interventions (4.4%, n = 10) were also reported. About one in four participants experienced nausea, vomiting and chills; fever was infrequent (2.5%, n = 5). For gestations 13-18 weeks, an outpatient day process for medication abortion is safe, effective and feasible. Medication abortion in 13 - 18 weeks need not be limited to inpatient care; nine of ten cases can be managed as an outpatient day service.
Identifiants
pubmed: 31491379
pii: S0010-7824(19)30404-4
doi: 10.1016/j.contraception.2019.08.007
pii:
doi:
Substances chimiques
Abortifacient Agents, Nonsteroidal
0
Abortifacient Agents, Steroidal
0
Misoprostol
0E43V0BB57
Mifepristone
320T6RNW1F
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
451-456Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.